Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Mark on +441494 818 049 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Mark Denton
Managing Director
+441494 818 049

Zenopa was extremely effective during my search for a new sales role. I was very pleased with the types of job role put forward and the consistent number of opportunities that my account manager conti...
Nina, 2013

Forest Laboratories receives EMA approval for Colobreathe

24 February 2012 00:00 in Pharmaceutical Company Product News

Forest Laboratories has been granted European regulatory approval for its new Colobreathe dry powder inhaler.

The European Medicines Agency (EMA) has ratified the dry powder colistimethate sodium inhaler for treating cystic fibrosis patients aged six years and older with chronic lung infections caused by P. aeruginosa.

Colobreathe has demonstrated its advantages compared to a leading competitor in a clinical trial, during which it was proven to offer better patient acceptability.

It will be introduced in Germany first in mid-2012, with a launch in the UK and other European nations to follow in September.

Raymond Stafford, chief executive officer of Forest Laboratories Europe, said: "Forest will be establishing affiliates in several additional European countries and some territories outside the EU to support the launch and commercialisation of Colobreathe, as well as additional products in the Forest pipeline."

Earlier this month, the company published new clinical data showing the efficacy of cariprazine, a treatment for acute mania associated with bipolar I disorder developed in partnership with Gedeon Richter.ADNFCR-8000103-ID-801301685-ADNFCR

Other news stories from 24/02/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2014 Zenopa Ltd